Semax is a synthetically produced heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) initially developed from adrenocorticotropic hormone (ACTH 4-10). It has been examined in laboratory settings for its potential neuroprotective, cognitive-enhancing, and neurorestorative characteristics. Investigations indicate Semax may affect the expression of brain-derived neurotrophic factor (BDNF), promote synaptic adaptability, and regulate the central nervous system’s compensatory responses to stress and damage. Supplied in a freeze-dried format, Semax is well-suited for controlled research environments concentrating on neurological and cognitive investigations.

Product Details

• Physical state: Freeze-dried powder
• Dissolution: Compatible with sterile water or research-appropriate buffer solutions
• Storage requirements: Store in dry conditions in a cool, dark location. Following reconstitution, maintain refrigeration at 2°C–8°C.

Research Context

Semax is investigated for its potential influence on:

• BDNF expression and neural cell generation
• Cognitive improvement and memory mechanisms
• CNS stress adaptation and neuroprotection
• Neurotransmitter system modulation

Important Notices

• Purpose: This compound is designated exclusively for in vitro research purposes. It is not to be utilized for human or animal administration, nor incorporated into any pharmaceutical, food, cosmetic, or diagnostic product.
• Regulatory Notice: The information supplied has not undergone FDA evaluation. This product is not meant to diagnose, treat, cure, or prevent any disease or condition. It is intended solely for application by qualified professionals in licensed laboratory settings.
• Purchase Agreement: By obtaining this product from Kairos Research Labs, the purchaser certifies that they are a qualified researcher and accepts complete responsibility for proper handling, application, and regulatory adherence. All sales are final.